PD-1 blocking antibody + Gemcitabine + Cisplatin (80 mg/m2) + Cisplatin (100 mg/m2) + Capecitabine
Phase 3Recruiting 0 views this week 0 watching⚡ Active
Interest: 47/100
47
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Nasopharyngeal Carcinoma
Conditions
Nasopharyngeal Carcinoma
Trial Timeline
Mar 1, 2024 → Feb 20, 2030
NCT ID
NCT06239727About PD-1 blocking antibody + Gemcitabine + Cisplatin (80 mg/m2) + Cisplatin (100 mg/m2) + Capecitabine
PD-1 blocking antibody + Gemcitabine + Cisplatin (80 mg/m2) + Cisplatin (100 mg/m2) + Capecitabine is a phase 3 stage product being developed by Sun Pharmaceutical for Nasopharyngeal Carcinoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06239727. Target conditions include Nasopharyngeal Carcinoma.
What happened to similar drugs?
0 of 12 similar drugs in Nasopharyngeal Carcinoma were approved
Approved (0) Terminated (0) Active (12)
Hype Score Breakdown
Clinical
17
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06239727 | Phase 3 | Recruiting |
Competing Products
20 competing products in Nasopharyngeal Carcinoma